Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications
Authors:
- Vivencio BarriosVBVivencio Barrios
- Carlos EscobarCECarlos Escobar
- 1 February 2013
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Cardiovascular Therapy
- Vol. 11 (2) , 129-141
Abstract
The majority of patients with nonvalvular atrial fibrillation (AF) will require anticoagulation therapy for reducing the risk of stroke, the most devastating complication of AF. Although traditionally vitamin K antagonists have been used for this purpose, they have important limitations that interfere with their use in clinical practice. Different clinical trials have shown the benefits of new oral anticoagulants over warfarin, but patients included in the ROCKET-AF trial were found to be at a higher risk of AF-related complications. Moreover, rivaroxaban has been proven to be effective and safe in patients with AF and moderate renal dysfunction as well as in those with ischemic heart disease. Rivaroxaban is taken only once daily; this may improve medication adherence and, secondarily, it provides a higher protection and reduction in the risk of stroke. This article provides an extensive review of the available evidence about rivaroxaban, with a special focus on nonvalvular AF.Keywords
This publication has 76 references indexed in Scilit:
- Cost–Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial FibrillationThe American Journal of Cardiology, 2012
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary EmbolismNew England Journal of Medicine, 2012
- Current Status of New Anticoagulants in the Management of Venous ThromboembolismAdvances in Hematology, 2012
- Antithrombotic Therapy for Atrial FibrillationChest, 2012
- RivaroxabanClinical Pharmacokinetics, 2011
- Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trialEuropean Heart Journal, 2011
- Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocolJournal of Thrombosis and Thrombolysis, 2011
- Control de los factores de riesgo en los pacientes hipertensos con cardiopatía isquémica crónica atendidos en las consultas de cardiología. Estudio CINHTIARevista Clínica Española, 2008
- Compliance with Antihypertensive Therapy in the ElderlyAmerican Journal of Cardiovascular Drugs, 2008
- Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study)The American Journal of Cardiology, 1994